Cargando…

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://www.ncbi.nlm.nih.gov/pubmed/30024784
http://dx.doi.org/10.1200/JCO.2017.77.6112
_version_ 1783353399084843008
author Lancet, Jeffrey E.
Uy, Geoffrey L.
Cortes, Jorge E.
Newell, Laura F.
Lin, Tara L.
Ritchie, Ellen K.
Stuart, Robert K.
Strickland, Stephen A.
Hogge, Donna
Solomon, Scott R.
Stone, Richard M.
Bixby, Dale L.
Kolitz, Jonathan E.
Schiller, Gary J.
Wieduwilt, Matthew J.
Ryan, Daniel H.
Hoering, Antje
Banerjee, Kamalika
Chiarella, Michael
Louie, Arthur C.
Medeiros, Bruno C.
author_facet Lancet, Jeffrey E.
Uy, Geoffrey L.
Cortes, Jorge E.
Newell, Laura F.
Lin, Tara L.
Ritchie, Ellen K.
Stuart, Robert K.
Strickland, Stephen A.
Hogge, Donna
Solomon, Scott R.
Stone, Richard M.
Bixby, Dale L.
Kolitz, Jonathan E.
Schiller, Gary J.
Wieduwilt, Matthew J.
Ryan, Daniel H.
Hoering, Antje
Banerjee, Kamalika
Chiarella, Michael
Louie, Arthur C.
Medeiros, Bruno C.
author_sort Lancet, Jeffrey E.
collection PubMed
description PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). PATIENTS AND METHODS: In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. RESULTS: CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. CONCLUSION: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.
format Online
Article
Text
id pubmed-6127025
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-61270252018-09-11 CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Lancet, Jeffrey E. Uy, Geoffrey L. Cortes, Jorge E. Newell, Laura F. Lin, Tara L. Ritchie, Ellen K. Stuart, Robert K. Strickland, Stephen A. Hogge, Donna Solomon, Scott R. Stone, Richard M. Bixby, Dale L. Kolitz, Jonathan E. Schiller, Gary J. Wieduwilt, Matthew J. Ryan, Daniel H. Hoering, Antje Banerjee, Kamalika Chiarella, Michael Louie, Arthur C. Medeiros, Bruno C. J Clin Oncol RAPID COMMUNICATION PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). PATIENTS AND METHODS: In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. RESULTS: CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. CONCLUSION: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy. American Society of Clinical Oncology 2018-09-10 2018-07-19 /pmc/articles/PMC6127025/ /pubmed/30024784 http://dx.doi.org/10.1200/JCO.2017.77.6112 Text en © 2018 by American Society of Clinical Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle RAPID COMMUNICATION
Lancet, Jeffrey E.
Uy, Geoffrey L.
Cortes, Jorge E.
Newell, Laura F.
Lin, Tara L.
Ritchie, Ellen K.
Stuart, Robert K.
Strickland, Stephen A.
Hogge, Donna
Solomon, Scott R.
Stone, Richard M.
Bixby, Dale L.
Kolitz, Jonathan E.
Schiller, Gary J.
Wieduwilt, Matthew J.
Ryan, Daniel H.
Hoering, Antje
Banerjee, Kamalika
Chiarella, Michael
Louie, Arthur C.
Medeiros, Bruno C.
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title_full CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title_fullStr CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title_full_unstemmed CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title_short CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
title_sort cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia
topic RAPID COMMUNICATION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://www.ncbi.nlm.nih.gov/pubmed/30024784
http://dx.doi.org/10.1200/JCO.2017.77.6112
work_keys_str_mv AT lancetjeffreye cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT uygeoffreyl cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT cortesjorgee cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT newelllauraf cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT lintaral cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT ritchieellenk cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT stuartrobertk cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT stricklandstephena cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT hoggedonna cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT solomonscottr cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT stonerichardm cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT bixbydalel cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT kolitzjonathane cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT schillergaryj cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT wieduwiltmatthewj cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT ryandanielh cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT hoeringantje cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT banerjeekamalika cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT chiarellamichael cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT louiearthurc cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia
AT medeirosbrunoc cpx351cytarabineanddaunorubicinliposomeforinjectionversusconventionalcytarabineplusdaunorubicininolderpatientswithnewlydiagnosedsecondaryacutemyeloidleukemia